Results 251 to 260 of about 15,170 (273)

The Use of α-fetoprotein for the Delivery of Cytotoxic Payloads to Cancer Cells

Therapeutic Delivery, 2014
One approach to improving the activity of anticancer drugs is to bind them to the human α-fetoprotein (HAFP) that recognizes the tumor-associated cell-surface HAFP receptor. A drug can be bound to the HAFP by covalent conjugation or within a non-covalent complex.
openaire   +2 more sources

Abstract 1319: Rapid accumulation of cytotoxic payload in tumor tissue drives BT5528 activity in tumor models

Cancer Research, 2021
Abstract BT5528 was developed as a Bicycle® toxin conjugate to deliver monomethyl auristatin E (MMAE) -payload to EphA2 overexpressing tumors. It consists of a bicyclic peptide targeting the tumor antigen EphA2, linked to the cytotoxin MMAE via a molecular spacer and cleavable linker.
Johanna Lahdenranta, Gavin Bennett, Philip Huxley, Gemma Mudd, Punit Upadhyaya, Phil Jeffrey, Nicholas Keen   +6 more
openaire   +1 more source

Double-Chambered Ferritin Platform: Dual-Function Payloads of Cytotoxic Peptides and Fluorescent Protein

Biomacromolecules, 2015
Ferritin cage nanoparticles are promising platforms for targeted delivery of imaging and therapeutic agents. One of the main advantages of cage nanoparticles is the ability to display multiple functionalities through genetic modification so as to achieve desired therapeutic or diagnostic functions.
Soyoun, Kim, Gwang Seob, Kim, Junyoung, Seo, Gunassekaran, Gowri Rangaswamy, In-Seop, So, Rang-Woon, Park, Byung-Heon, Lee, In-San, Kim   +7 more
openaire   +2 more sources

Factors Involved in the Design of Cytotoxic Payloads for Antibody–Drug Conjugates

2012
Selective targeting of cancer can be accomplished by the use of monoclonal antibodies (mAbs) that bind to tumor-associated antigens expressed preferentially on the surface of cancer cells. Several of these non-derivatized antibodies, or naked antibodies, have been approved for the treatment of various cancer types.
Wayne C. Widdison, Ravi V. J. Chari
openaire   +1 more source

Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads

Molecular Cancer Therapeutics
Abstract Antibody–drug conjugates (ADC) have recently emerged as an effective treatment option for cancer. Although the fundamental mechanisms of direct tumor cell killing by various ADC payloads have been established, their impact on the tumor microenvironment (TME) remains underexplored.
Srishti Chakravorty, Yulia Zybina, Eunseon Ahn, Komal Pradhan, Ni Yu, Marlene Taylor, Manoj Charati, Douglas C. Wilson, Albert B. Jeon, Wendy M. Blumenschein, Jin-Hwan Han   +10 more
openaire   +2 more sources

Cytotoxic Payloads for Antibody – Drug Conjugates

2019
Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin (Mylotarg™) and moxetumomab pasudotox-tdfk (Lumoxiti ...
openaire   +1 more source

Development of immunoliposomes containing cytotoxic gold payloads against HER2-positive breast cancers

RSC Medicinal Chemistry
HER2-targeted immunoliposomes with gold payloads exhibit greater accumulation than non-targeted liposomes and free gold compounds and localize in the mitochondria and endoplasmic reticulum leading to cell death at lower nanomolar drug concentrations.
Afruja Ahad, Fatima Aftab, Alexa Michel, Jason S. Lewis, Maria Contel   +4 more
openaire   +2 more sources

Strategies to reduce the use of non-human primates in development of oncology ADCs with cytotoxic payloads

Regulatory Toxicology and Pharmacology
The use of non-human primates (NHP) for the nonclinical development of biologics can be necessary to assess the potential safety risks in humans. An IQ DruSafe and 3Rs TPS Working Group (WG) conducted a survey on the use of NHP in toxicology studies used to develop antibody drug conjugates (ADCs) with cytotoxic payloads for oncology treatment.
Sherry L. Ralston, Li Li, Donna Lee, Darcey Clark, Andrew Dropsey, Haley Neff-LaFord, Payal Rana, Lucinda Weir, Radhakrishna Sura, Natalie Waterhouse   +9 more
openaire   +2 more sources

Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates

Journal of Chromatography A, 2016
UV spectrophotometry is widely used to determine the molar extinction coefficients (MECs) of cytotoxic drugs as well as the drug antibody ratios (DARs) of antibody drug conjugates (ADCs). However, the unknown purity of a drug due to interfering impurities can lead to erroneous MECs and DARs.
Chunlei, Wang, Sike, Chen, Janet, Caceres-Cortes, Richard Y-C, Huang, Adrienne A, Tymiak, Yingru, Zhang   +5 more
openaire   +2 more sources

Abstract 314: Improved tumor penetration and cytotoxic payload release with TD001, a novel PSMA-targeting ADC with optimized linker-payload composition, in PSMA-expressing CRPC CDX castrated mouse models

Cancer Research
Abstract Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein belonging to the folate receptor family, is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), and increases following androgen deprivation therapy (ADT).
Daniela Impellizzieri, Elisa Storelli, Atik Balla, Simone Mosole, Cristina Dongilli, Federico Jauk, Roberta Frapolli, Lavinia Morosi, Maurizio D'Incalci, Jemila Houacine, Morris Rosenberg, Bérangère Deleglise, Esteban Cvitkovic, Carlo V. Catapano   +13 more
openaire   +1 more source